Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The effects on risk of diabetes were assessed by a genetic score using two 25(OH)D synthesis SNPs (DHCR7-rs12785878 and CYP2R1-rs10741657), with and without the addition of SNPs affecting the transport (GC/DBP-rs2282679) and catabolism (CYP24A1-rs6013897) of 25(OH)D.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Genetic instrumental-variable study.

Genetic instrumental-variable study

Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.

Meta-analysis reported · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Association of vitamin D with risk of type 2 diabetes: A Mendelian randomisation study in European and Chinese adults

Source: Article title.

The 512,891 participants were enrolled from 10 geographically diverse urban and rural areas in China.

Source: Methods.

Using the search terms “genetic studies of plasma 25(OH)D concentrations” or “genetic studies of vitamin D” or “diabetes”, we sought to identify further genetic studies, in addition to those included in a previous meta-analysis in 2015, for 25(OH)D and risk of diabetes using the PubMed and Web of Science databases [].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Association of vitamin D with risk of type 2 diabetes: A Mendelian randomisation study in European and Chinese adults

Genetic instrumental-variable study · PLoS Medicine · 2018

Original publication title

Association of vitamin D with risk of type 2 diabetes: A Mendelian randomisation study in European and Chinese adults

Ling Lu; Derrick A. Bennett; Iona Y. Millwood; Sarah Parish; Mark I. McCarthy; Anubha Mahajan; Xu Lin; Fiona Bragg; Yu Guo; Michael V. Holmes; Shoaib Afzal; Børge G. Nordestgaard; Zheng Bian; Michael Hill; Robin G. Walters; Liming Li; Zhengming Chen; Robert Clarke

© 2018 Lu et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The concordant risks of diabetes for biochemically measured and genetically instrumented differences in 25(OH)D using synthesis SNPs provide evidence for a causal effect of higher 25(OH)D for prevention of diabetes.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Observational studies have reported that higher plasma 25-hydroxyvitamin D (25[OH]D) concentrations are associated with lower risks of diabetes, but it is unclear if these associations are causal. The aim of this study was to test the relevance of 25(OH)D for type 2 diabetes using genetically instrumented differences in plasma 25(OH)D concentrations.

Source: Background

Abstract: Methods and findings

Data were available on four 25(OH)D single nucleotide polymorphisms (SNPs; n = 82,464), plasma 25(OH)D concentrations (n = 13,565), and cases with diabetes (n = 5,565) in the China Kadoorie Biobank (CKB). The effects on risk of diabetes were assessed by a genetic score using two 25(OH)D synthesis SNPs (DHCR7-rs12785878 and CYP2R1-rs10741657), with and without the addition of SNPs affecting the transport (GC/DBP-rs2282679) and catabolism (CYP24A1-rs6013897) of 25(OH)D. The CKB results were combined in a meta-analysis of 10 studies for the 2 synthesis SNPs (n = 58,312 cases) and 7 studies for all 4 SNPs (n = 32,796 cases).

Mean (SD) 25(OH)D concentration was 62 (20) nmol/l in CKB, and the per allele effects of genetic scores on 25(OH)D were 2.87 (SE 0.39) for the synthesis SNPs and 3.54 (SE 0.32) for all SNPs. A 25-nmol/l higher biochemically measured 25(OH)D was associated with a 9% (95% CI: 0%: 18%) lower risk of diabetes in CKB. In a meta-analysis of all studies, a 25-nmol/l higher genetically instrumented 25(OH)D concentration was associated with a 14% (95% CI: 3%: 23%) lower risk of diabetes (p = 0.01) using the 2 synthesis SNPs.

An equivalent difference in 25(OH)D using a genetic score with 4 SNPs was not significantly associated with diabetes (odds ratio 8%, 95% CI: −1% to 16%, lower risk, p = 0.07), but had some evidence of pleiotropy. A limitation of the meta-analysis was the access only to study level rather than individual level data.

Source: Methods and findings

Abstract: Why was this study done?

  • There is a debate about whether low vitamin D status increases the risk of diabetes or is just a marker of overall poor health. Observational studies have demonstrated that individuals with higher vitamin D status in European populations have lower risks of developing type 2 diabetes.

Source: Why was this study done?

Abstract: What did the researchers do and find?

  • The present report, involving approximately 82,500 adults living in China, replicated the association of higher vitamin D status with lower risk of type 2 diabetes in Chinese adults.

  • A combined analysis of over 58,000 cases and 370,000 controls in European and Chinese adults demonstrated that genetically instrumented increases in a circulating marker of vitamin D status, corresponding to increases achievable by vitamin D supplements, were associated with a 14% lower risk of diabetes.

Source: What did the researchers do and find?

Abstract: What do these findings mean?

  • The concordant results of both the observational studies and the genetic studies indicate that higher vitamin D status is associated with lower risk of diabetes and provide support for a causally protective effect of higher vitamin D status for prevention of type 2 diabetes.

Source: What do these findings mean?

Abstract: Conclusions

The concordant risks of diabetes for biochemically measured and genetically instrumented differences in 25(OH)D using synthesis SNPs provide evidence for a causal effect of higher 25(OH)D for prevention of diabetes.

Source: Conclusions
Authors’ abstract

Background

Observational studies have reported that higher plasma 25-hydroxyvitamin D (25[OH]D) concentrations are associated with lower risks of diabetes, but it is unclear if these associations are causal. The aim of this study was to test the relevance of 25(OH)D for type 2 diabetes using genetically instrumented differences in plasma 25(OH)D concentrations.

Methods and findings

Data were available on four 25(OH)D single nucleotide polymorphisms (SNPs; n = 82,464), plasma 25(OH)D concentrations (n = 13,565), and cases with diabetes (n = 5,565) in the China Kadoorie Biobank (CKB). The effects on risk of diabetes were assessed by a genetic score using two 25(OH)D synthesis SNPs (DHCR7-rs12785878 and CYP2R1-rs10741657), with and without the addition of SNPs affecting the transport (GC/DBP-rs2282679) and catabolism (CYP24A1-rs6013897) of 25(OH)D. The CKB results were combined in a meta-analysis of 10 studies for the 2 synthesis SNPs (n = 58,312 cases) and 7 studies for all 4 SNPs (n = 32,796 cases).

Mean (SD) 25(OH)D concentration was 62 (20) nmol/l in CKB, and the per allele effects of genetic scores on 25(OH)D were 2.87 (SE 0.39) for the synthesis SNPs and 3.54 (SE 0.32) for all SNPs. A 25-nmol/l higher biochemically measured 25(OH)D was associated with a 9% (95% CI: 0%: 18%) lower risk of diabetes in CKB. In a meta-analysis of all studies, a 25-nmol/l higher genetically instrumented 25(OH)D concentration was associated with a 14% (95% CI: 3%: 23%) lower risk of diabetes (p = 0.01) using the 2 synthesis SNPs.

An equivalent difference in 25(OH)D using a genetic score with 4 SNPs was not significantly associated with diabetes (odds ratio 8%, 95% CI: −1% to 16%, lower risk, p = 0.07), but had some evidence of pleiotropy. A limitation of the meta-analysis was the access only to study level rather than individual level data.

Conclusions

The concordant risks of diabetes for biochemically measured and genetically instrumented differences in 25(OH)D using synthesis SNPs provide evidence for a causal effect of higher 25(OH)D for prevention of diabetes.

Author summary

Why was this study done?

  • There is a debate about whether low vitamin D status increases the risk of diabetes or is just a marker of overall poor health. Observational studies have demonstrated that individuals with higher vitamin D status in European populations have lower risks of developing type 2 diabetes.

What did the researchers do and find?

  • The present report, involving approximately 82,500 adults living in China, replicated the association of higher vitamin D status with lower risk of type 2 diabetes in Chinese adults.

  • A combined analysis of over 58,000 cases and 370,000 controls in European and Chinese adults demonstrated that genetically instrumented increases in a circulating marker of vitamin D status, corresponding to increases achievable by vitamin D supplements, were associated with a 14% lower risk of diabetes.

What do these findings mean?

  • The concordant results of both the observational studies and the genetic studies indicate that higher vitamin D status is associated with lower risk of diabetes and provide support for a causally protective effect of higher vitamin D status for prevention of type 2 diabetes.

Publication and source details

Original title: Association of vitamin D with risk of type 2 diabetes: A Mendelian randomisation study in European and Chinese adults

Ling Lu; Derrick A. Bennett; Iona Y. Millwood; Sarah Parish; Mark I. McCarthy; Anubha Mahajan; Xu Lin; Fiona Bragg; Yu Guo; Michael V. Holmes; Shoaib Afzal; Børge G. Nordestgaard; Zheng Bian; Michael Hill; Robin G. Walters; Liming Li; Zhengming Chen; Robert Clarke

PLoS Medicine · 2018

I have read the journal’s policy and the authors of this manuscript have the following competing interests: MIM serves on Advisory Panels for Pfizer and NovoNordisk, and has received honoraria from Pfizer, Eli Lilly and NovoNordisk. He receives research funding from Pfizer, Eli Lilly, NovoNordisk, Merck, Takeda, Janssen, Servier, Sanofi-Aventis, Astra Zeneca, Roche, and Boehringer Ingelheim.

‡ These authors are joint senior authors on this work.

* E-mail: robert.clarke@ndph.ox.ac.uk
© 2018 Lu et al2018Lu et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/100004440Wellcome Trust202922/Z/16/ZChen Zhengming http://dx.doi.org/10.13039/100004440Wellcome Trust104085/Z/14/ZChen Zhengming http://dx.doi.org/10.13039/100004440Wellcome Trust088158/Z/09/ZChen Zhengming http://dx.doi.org/10.13039/100004440Wellcome Trust088158/Z/09/ZChen Zhengming http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of China81390540Li Liming http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of China81390541Li Liming http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of China81390544Li Liming http://dx.doi.org/10.13039/501100000265Medical Research CouncilMC_PC_13049Chen Zhengming http://dx.doi.org/10.13039/501100000265Medical Research CouncilMC-PC-14135Chen Zhengming http://dx.doi.org/10.13039/501100002855Ministry of Science and Technology of the People’s Republic of China2011BAI09B01Li Liming http://dx.doi.org/10.13039/501100000274British Heart Foundationcore fundingChen Zhengming UK Medical Research Councilcore fundingChen Zhengming http://dx.doi.org/10.13039/501100000289Cancer Research UKcore fundingChen Zhengming http://dx.doi.org/10.13039/100004440Wellcome Trust098381http://orcid.org/0000-0002-4393-0510McCarthy Mark I. The CKB baseline survey and the first re-survey were supported by the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up has been supported by the UK Wellcome Trust (202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and grants from the National Natural Science Foundation of China (81390540, 81390541, 81390544). DNA extraction and genotyping were supported by grants from GlaxoSmithKline and the UK Medical Research Council (MC_PC_13049, MC-PC-14135). The CKB study also received support from the Ministry of Science and Technology of the People’s Republic of China (2011BAI09B01). The British Heart Foundation, UK Medical Research Council and Cancer Research UK provide core funding to the Clinical Trial Service Unit and Epidemiological Studies Unit at Oxford University for the project. MIM received a grant from the Wellcome Trust (098381). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:39:00.665477+00:00

DOI: 10.1371/journal.pmed.1002566 · PMC5931494